Quantitative systems pharmacology modeling provides insight into inter-mouse variability of Anti-CTLA4 response

Area of Science:

• Immunology
• Pharmacology
• Computational Biology

Background:

• Clinical responses to immuno-oncology therapies exhibit significant patient-to-patient variability.
• Similar variability is observed in syngeneic mouse models, necessitating investigation into underlying mechanisms.

Purpose of the Study:

• To develop a quantitative systems pharmacology (QSP) model to understand variability in anti-CTLA4 therapy response in mice.
• To identify key biological factors driving inter-animal variability in tumor growth dynamics.

Main Methods:

• A QSP model was constructed to simulate molecular and cellular interactions of anti-CTLA4 therapy.
• Nonlinear mixed-effects modeling was employed to analyze tumor growth variability across individual animals.
• Simulations were performed to explore potential strategies for converting non-responders to responders.

Main Results:

• Intratumoral CD8+ T cell kinetics and tumor proliferation rates were identified as primary drivers of response variability.
• Model simulations demonstrated that increasing intratumoral CD8+ T cell numbers could convert non-responsive mice to responders.
• The model successfully captured inter-animal variability in tumor growth profiles under anti-CTLA4 treatment.

Conclusions:

• The developed QSP model provides a mechanistic framework for understanding anti-CTLA4 therapy variability in preclinical models.
• Findings suggest that modulating intratumoral CD8+ T cell populations is a potential strategy to enhance treatment efficacy.
• This work serves as a foundation for translating insights from mouse models to clinical applications of CTLA4 inhibitors.